{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:01:34Z","timestamp":1784541694615,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic resistance remains a prevalent and intractable clinical challenge across a broad spectrum of human malignancies. Despite extensive investigations, the intricate molecular networks by which the tumor microenvironment (TME) mediates such resistance are not fully understood. In this study, we identified nucleotide-binding oligomerization domain-containing proteins 1 and 2 (NOD1\/2) as pivotal regulators of adaptive resistance to diverse antitumor therapies, including immune checkpoint blockade (ICB), adoptive T-cell therapy, and cytotoxic chemotherapy. In murine tumor models, genetic ablation of NOD1\/2 or receptor-interacting protein kinase 2 (RIPK2), as well as pharmacological inhibition of RIPK2, remodeled the TME by decreasing immunosuppressive macrophages and boosting CD8\u207a T cell infiltration and cytotoxicity. Mechanistically, NOD1\/2 activation in macrophages upregulated programmed death-ligand 1 (PD-L1) expression via the RIPK2\/NF-\u03baB signaling axis, establishing an immunosuppressive TME that impaired CD8\u207a T cell-mediated antitumor immunity. Notably, in the clinically relevant setting of immunotherapy resistance, targeted suppression of NOD1\/2 signaling in patient-derived peripheral blood mononuclear cells (PBMCs) restored and potentiated ICB responsiveness in patient-derived tumor organoids. Bioinformatic analyses further demonstrated that NOD1\/2-associated gene signatures were significantly enriched in tumor-associated macrophages post-therapy. Our findings define NOD1\/2 as a novel innate immune checkpoint that orchestrates therapy-induced adaptive resistance and highlight this pathway as a promising target to overcome treatment resistance in refractory cancers.<\/jats:p>","DOI":"10.1038\/s41392-026-02758-6","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:22:04Z","timestamp":1784532124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NOD1\/2 signaling in macrophages drives adaptive immune resistance in cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiduan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7731-2147","authenticated-orcid":false,"given":"Xuerui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-7867","authenticated-orcid":false,"given":"Yiran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-0970","authenticated-orcid":false,"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2758_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA-Cancer J. Clin."},{"key":"2758_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2758_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals, P. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286\u2013301 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2758_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-025-01760-9","volume":"18","author":"WZ Li","year":"2025","unstructured":"Li, W. Z., Zhao, D. F., Chen, M. & Yan, X. J. Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting. J. Hematol. Oncol. 18, 104 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2758_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","volume":"18","author":"LL Huang","year":"2025","unstructured":"Huang, L. L., Zhu, H. H. & Shi, Y. K. Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025). J. Hematol. Oncol. 18, 107 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2758_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. P. Adaptive immune resistance at the tumor site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2758_CR7","first-page":"V","volume":"1036","author":"P Kalinski","year":"2017","unstructured":"Kalinski, P. Tumor immune microenvironment in cancer progression and cancer therapy preface. Adv. Exp. Med. Biol. 1036, V\u2013Vi (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2758_CR8","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau, C. et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat. Genet. 56, 2466\u20132478 (2024).","journal-title":"Nat. Genet."},{"key":"2758_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2758_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.immuni.2014.12.010","volume":"41","author":"R Caruso","year":"2014","unstructured":"Caruso, R., Warner, N., Inohara, N. & N\u00fa\u00f1ez, G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 41, 898\u2013908 (2014).","journal-title":"Immunity"},{"key":"2758_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri1747","volume":"6","author":"W Strober","year":"2006","unstructured":"Strober, W., Murray, P. J., Kitani, A. & Watanabe, T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6, 9\u201320 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"2758_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1126\/science.aau6391","volume":"366","author":"Y Lu","year":"2019","unstructured":"Lu, Y. et al. Palmitoylation of NOD1 and NOD2 is required for bacterial sensing. Science 366, 460\u2013467 (2019).","journal-title":"Science"},{"key":"2758_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1084\/jem.20051229","volume":"203","author":"J Masumoto","year":"2006","unstructured":"Masumoto, J. et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J. Exp. Med. 203, 203\u2013213 (2006).","journal-title":"J. Exp. Med."},{"key":"2758_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.1104911","volume":"307","author":"KS Kobayashi","year":"2005","unstructured":"Kobayashi, K. S. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307, 731\u2013734 (2005).","journal-title":"Science"},{"key":"2758_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02248-w","volume":"20","author":"YY Zhang","year":"2022","unstructured":"Zhang, Y. Y. et al. Upregulation of NOD1 and NOD2 contribute to cancer progression through the positive regulation of tumorigenicity and metastasis in human squamous cervical cancer. Bmc Med. 20, 55 (2022).","journal-title":"Bmc Med."},{"key":"2758_CR16","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1073\/pnas.0509228103","volume":"103","author":"JD Correia","year":"2006","unstructured":"Correia, J. D. et al. Nod1-dependent control of tumor growth. Proc. Natl. Acad. Sci. USA. 103, 1840\u20131845 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2758_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13238-019-00687-5","volume":"11","author":"HY Jiang","year":"2020","unstructured":"Jiang, H. Y. et al. Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis. Protein Cell 11, 187\u2013201 (2020).","journal-title":"Protein Cell"},{"key":"2758_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-020-01028-4","volume":"14","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. J. Hematol. Oncol. 14, 9 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2758_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00432-022-04354-x","volume":"149","author":"XZ Li","year":"2023","unstructured":"Li, X. Z. et al. NOD2 inhibits the proliferation of esophageal adenocarcinoma cells through autophagy. J. Cancer Res. Clin. 149, 639\u2013652 (2023).","journal-title":"J. Cancer Res. Clin."},{"key":"2758_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07104-8","volume":"15","author":"F Yun","year":"2024","unstructured":"Yun, F. et al. NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS\/PLK1 signaling axis. Cell Death Dis. 15, 720 (2024).","journal-title":"Cell Death Dis."},{"key":"2758_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108677","volume":"34","author":"C Maisonneuve","year":"2021","unstructured":"Maisonneuve, C. et al. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell Rep. 34, 108677 (2021).","journal-title":"Cell Rep."},{"key":"2758_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12264","volume":"11","author":"XD Wei","year":"2022","unstructured":"Wei, X. D. et al. Extracellular vesicles from colorectal cancer cells promote metastasis via the NOD1 signaling pathway. J. Extracell. Vesicles 11, e12264 (2022).","journal-title":"J. Extracell. Vesicles"},{"key":"2758_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp8266","volume":"10","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Activation of NOD1 on tumor-associated macrophages augments CD8(+) T cell-mediated antitumor immunity in hepatocellular carcinoma. Sci. Adv. 10, eadp8266 (2024).","journal-title":"Sci. Adv."},{"key":"2758_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daill\u00e8re","year":"2016","unstructured":"Daill\u00e8re, R. et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity 45, 931\u2013943 (2016).","journal-title":"Immunity"},{"key":"2758_CR25","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.abc9113","volume":"373","author":"ME Griffin","year":"2021","unstructured":"Griffin, M. E. et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373, 1040\u20131046 (2021).","journal-title":"Science"},{"key":"2758_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112723","volume":"207","author":"Y Ma","year":"2020","unstructured":"Ma, Y. et al. Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1\/2 antagonists for adjuvant cancer chemotherapy. Eur. J. Med. Chem. 207, 112723 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2758_CR27","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1021\/jm101577z","volume":"54","author":"Y Ma","year":"2011","unstructured":"Ma, Y., Zhao, N. & Liu, G. Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice. J. Med. Chem. 54, 2767\u20132777 (2011).","journal-title":"J. Med. Chem."},{"key":"2758_CR28","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acs.jmedchem.7b01407","volume":"61","author":"XM Wen","year":"2018","unstructured":"Wen, X. M. et al. Salutaxel, a conjugate of docetaxel and a muramyl dipeptide (MDP) Analogue, acts as multifunctional prodrug that inhibits tumor growth and metastasis. J. Med. Chem. 61, 1519\u20131540 (2018).","journal-title":"J. Med. Chem."},{"key":"2758_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32583-z","volume":"8","author":"A Butera","year":"2018","unstructured":"Butera, A. et al. Nod2 deficiency in mice is associated with microbiota variation favouring the expansion of mucosal CD4+LAP+ regulatory cells. Sci. Rep. 8, 14241 (2018).","journal-title":"Sci. Rep."},{"key":"2758_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/eji.201040827","volume":"41","author":"JG Magalhaes","year":"2011","unstructured":"Magalhaes, J. G. et al. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur. J. Immunol. 41, 1445\u20131455 (2011).","journal-title":"Eur. J. Immunol."},{"key":"2758_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202419969","volume":"37","author":"MQ Gao","year":"2025","unstructured":"Gao, M. Q. et al. Cell surface-tethered nucleic acid therapeutics program robust and tumor-responsive enhancement of adoptive cell therapy. Adv. Mater. 37, e2419969 (2025).","journal-title":"Adv. Mater."},{"key":"2758_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"2758_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep31726","volume":"6","author":"C Nicolazzo","year":"2016","unstructured":"Nicolazzo, C. et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 6, 31726 (2016).","journal-title":"Sci. Rep."},{"key":"2758_CR34","doi-asserted-by":"publisher","first-page":"D1391","DOI":"10.1093\/nar\/gkab804","volume":"50","author":"ZX Zeng","year":"2022","unstructured":"Zeng, Z. X. et al. TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Res. 50, D1391\u2013D1397 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2758_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271\u20131281 (2018).","journal-title":"Nat. Genet."},{"key":"2758_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo, C. M. et al. Tumor organoid-T-cell coculture systems. Nat. Protoc. 15, 15\u201339 (2020).","journal-title":"Nat. Protoc."},{"key":"2758_CR37","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586\u20131598.e1512 (2018).","journal-title":"Cell"},{"key":"2758_CR38","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"YQ Chen","year":"2024","unstructured":"Chen, Y. Q. et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42, 1268\u20131285.e1267 (2024).","journal-title":"Cancer Cell"},{"key":"2758_CR39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"LC Ma","year":"2019","unstructured":"Ma, L. C. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 36, 418\u2013430.e416 (2019).","journal-title":"Cancer Cell"},{"key":"2758_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","volume":"43","author":"YY Zhang","year":"2025","unstructured":"Zhang, Y. Y. et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell 43, 446\u2013463.e447 (2025).","journal-title":"Cancer Cell"},{"key":"2758_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2758_CR42","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. H. Tumor microenvironment as a therapeutic target in cancer. Pharm. Therapeut 221, 107753 (2021).","journal-title":"Pharm. Therapeut"},{"key":"2758_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"2758_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2758_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2758_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"2758_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"2758_CR48","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"2758_CR49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"YF Li","year":"2024","unstructured":"Li, Y. F. et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut 74, 350\u2013363 (2024).","journal-title":"Gut"},{"key":"2758_CR50","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nbt1215-1217","volume":"33","author":"K Garber","year":"2015","unstructured":"Garber, K. Predictive biomarkers for checkpoints, first tests approved. Nat. Biotechnol. 33, 1217\u20131218 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2758_CR51","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"WP Zou","year":"2016","unstructured":"Zou, W. P., Wolchok, J. D. & Chen, L. P. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2758_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4853-0","volume":"18","author":"R Cantero-Cid","year":"2018","unstructured":"Cantero-Cid, R. et al. PD-L1\/PD-1 crosstalk in colorectal cancer: are we targeting the right cells? Bmc Cancer 18, 945 (2018).","journal-title":"Bmc Cancer"},{"key":"2758_CR53","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard, E. et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J. Clin. Investig. 130, 5380\u20135396 (2020).","journal-title":"J. Clin. Investig."},{"key":"2758_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).","journal-title":"Nat. Commun."},{"key":"2758_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2022.07.004","volume":"67","author":"W Li","year":"2022","unstructured":"Li, W. et al. Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy. Cytokine Growth Factor Rev. 67, 49\u201357 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2758_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.930797","volume":"9","author":"V Quagliariello","year":"2022","unstructured":"Quagliariello, V. et al. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front. Cardiovasc Med. 9, 930797 (2022).","journal-title":"Front. Cardiovasc Med."},{"key":"2758_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ccell.2025.12.005","volume":"44","author":"L Galluzzi","year":"2026","unstructured":"Galluzzi, L. et al. Cancer cell death: cell-autonomous and immunogenic dimensions. Cancer Cell 44, 281\u2013305 (2026).","journal-title":"Cancer Cell"},{"key":"2758_CR58","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179\u2013U167 (2012).","journal-title":"Nature"},{"key":"2758_CR59","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"LL Wang","year":"2023","unstructured":"Wang, L. L. et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell 41, 1294\u20131308.e1298 (2023).","journal-title":"Cancer Cell"},{"key":"2758_CR60","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1093\/nar\/gkae183","volume":"52","author":"XL Hu","year":"2024","unstructured":"Hu, X. L. et al. Dux activates metabolism-lactylation-MET network during early iPSC reprogramming with Brg1 as the histone lactylation reader. Nucleic Acids Res. 52, 5529\u20135548 (2024).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02758-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:02:12Z","timestamp":1784538132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02758-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2758"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02758-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"300"}}